{"id":"etiroxate","rwe":[{"pmid":"3879914","year":"1985","title":"[The effect of repeated administration of triiodothyronine or etiroxate on liver regeneration in rats after partial hepatectomy].","finding":"","journal":"Sbornik vedeckych praci Lekarske fakulty Karlovy univerzity v Hradci Kralove. Supplementum","studyType":"Clinical Study"},{"pmid":"6241723","year":"1984","title":"Effect of triiodothyronine or etiroxate on DNA synthesis in intact and regenerating liver.","finding":"","journal":"Physiologia Bohemoslovaca","studyType":"Clinical Study"},{"pmid":"7093991","year":"1982","title":"[Etiroxate treatment for hyperlipoproteinaemia type IIa and IIb (author's transl)].","finding":"","journal":"Casopis lekaru ceskych","studyType":"Clinical Study"},{"pmid":"7073804","year":"1982","title":"Rate of LCAT-mediated cholesterol esterification and serum lipids during etiroxate therapy in hyperlipoproteinemia.","finding":"","journal":"Atherosclerosis","studyType":"Clinical Study"},{"pmid":"7075390","year":"1982","title":"Cholesterol turnover and risk factors for the development of coronary heart disease.","finding":"","journal":"Czechoslovak medicine","studyType":"Clinical Study"}],"tags":[{"label":"etiroxate","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Antimetabolites","category":"pharmacology"},{"label":"Hypolipidemic Agents","category":"pharmacology"},{"label":"Lipid Regulating Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["etiroxate"],"offLabel":[],"synonyms":["etiroxate"],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"etiroxate","explanation":"Imagine your blood as a liquid with tiny particles called platelets that help it clot when you're injured. Etiroxate is thought to slow down the movement of these platelets, making it harder for them to clump together and form clots. This can help prevent blood clots from forming in the first place.","oneSentence":"Etiroxate works by inhibiting platelet aggregation, but the exact molecular details are unclear.","technicalDetail":"Etiroxate is believed to exert its effects by inhibiting the enzyme ADP, which plays a key role in platelet activation and aggregation."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3210","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ETIROXATE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T14:53:39.378230","biosimilars":[],"competitors":[],"genericName":"etiroxate","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"0S3LDN5P7H","INN_ID":"3603","UMLSCUI":"C0059861","ChEMBL_ID":"CHEMBL2104225","PUBCHEM_CID":"65683","MESH_SUPPLEMENTAL_RECORD_UI":"C010150"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":16,"therapeuticAreas":["Hematology"],"biosimilarFilings":[],"recentPublications":[{"date":"1985","pmid":"3879914","title":"[The effect of repeated administration of triiodothyronine or etiroxate on liver regeneration in rats after partial hepatectomy].","journal":"Sbornik vedeckych praci Lekarske fakulty Karlovy univerzity v Hradci Kralove. Supplementum"},{"date":"1984","pmid":"6241723","title":"Effect of triiodothyronine or etiroxate on DNA synthesis in intact and regenerating liver.","journal":"Physiologia Bohemoslovaca"},{"date":"1982 May 14","pmid":"7093991","title":"[Etiroxate treatment for hyperlipoproteinaemia type IIa and IIb (author's transl)].","journal":"Casopis lekaru ceskych"},{"date":"1982 Apr","pmid":"7073804","title":"Rate of LCAT-mediated cholesterol esterification and serum lipids during etiroxate therapy in hyperlipoproteinemia.","journal":"Atherosclerosis"},{"date":"1982","pmid":"7075390","title":"Cholesterol turnover and risk factors for the development of coronary heart disease.","journal":"Czechoslovak medicine"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"ETIROXATE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etiroxate is a small molecule drug in the etiroxate class, but its target and exact mechanism of action are unknown. It is not clear if it is FDA-approved or commercially available. Etiroxate's indications, half-life, bioavailability, and generic manufacturers are also unknown. As a result, there is limited information available on its commercial status, safety considerations, or off-patent status. Further research is needed to understand this drug's properties and potential uses.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}